Millendo Therapeutics

Millendo Therapeutics

closed

Atterocor focuses on research and development of therapeutics for adrenal disease.

HQ location
Ann Arbor, United States
Founding location
Écully, France
Website
millendo.com
Launch date
Employees
2-10 people
Enterprise value
$120—180m
Company register number
497575621
Recent deals
https://www.linkedin.com/company/millendo-therapeutics-ltd
    • Edit
loading funding rounds…
NEA
NEA(exited)
Adams Street Partners
Adams Street Partners(exited)
Frazier Healthcare Partners
Frazier Healthcare Partners(exited)
Altitude Life Science Ventures
Altitude Life Science Ventures(exited)
Roche Venture Fund
Roche Venture Fund(exited)
Longwood Fund
Longwood Fund(exited)
5AM Ventures
5AM Ventures(exited)
Renaissance Venture Capital Fund
Renaissance Venture Capital Fund(exited)
Osage University Partners
Osage University Partners(exited)
Ann Arbor Spark
Ann Arbor Spark(exited)
Turenne Capital
Turenne Capital(exited)
Tempest Therapeutics
Tempest Therapeutics

Related Content

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Millendo Therapeutics

Edit
Amolyt Pharma
Amolyt Pharma
ACQUISITION by AstraZeneca Mar 2024
OvaScience
OvaScience
ACQUISITION by Millendo Therapeutics Aug 2018
Tempest Therapeutics
Tempest Therapeutics
exited